Walgreens gains (WBA) Q2 2025

Walgreens Tuesday, profits and income from the second financial quarter that exceeded expectations, because the retail pharmacy giant benefits from cost reductions and is preparing to become private.

The company is being deprived by Sycamore Partners in an agreement of approximately $ 10 billion which is expected to conclude in the fourth quarter of this year. Walgreens withdrew its directives for the 2025 financial year given the pending transaction. In January, he said he expected an adjusted benefit in year full of $ 1.40 to $ 1.80 per share.

The historic agreement with Sycamore puts an end to the tumultuous race of Walgreens as a public company, which began in 1927. The company closes the stores and reduces other costs because it is in a hurry by the reimbursement of the pharmacy, the opposite winds, the softer consumption expenses and the competition of its main rival rival rival CVSRetail grocery stores and chains, and Amazon. He is also struggling with a push disturbed in health care.

Walgreens’ actions increased by almost 2% in pre-commercial exchanges on Tuesday.

Here is what Walgreens reported for the three -month period ended on February 28 in relation to what Wall Street was waiting, on the basis of an investigation of LSEG analysts:

• Profit by action: 63 cents adjusted vs 53 cents expected
• Income: $ 38.59 billion against $ 38 billion expected

“The results of the second quarter reflect the management of disciplined costs and the improvement of American health care, which were partially offset by lower frontal results in the retail pharmacy in the United States, while important legal establishments have led to a continuation of the available negative cash flows,” said Walgreens CEO, Tim Wentworth, in a press release.

“We remain in the first stages of our recovery plan, and continue to expect that the creation of significant value takes time, the improved concentration and the balance of future cash needs with the investments necessary to navigate in a changing pharmacy and a retail landscape,” he added.

During the second tax quarter, Walgreens reserved sales of $ 38.59 billion, up 4.1% compared to the same period a year ago, as sales increased in its retail pharmacy in the United States and its international segments.

The company declared a net loss of $ 2.85 billion, or $ 3.30 per share, for the second tax quarter. He compared to a net loss of $ 5.91 billion, or $ 6.85 per share, during the annual period.

Excluding certain articles, the adjusted profits were 63 cents per action for the quarter.

The results include costs of $ 4.2 billion linked to a loss of value of its American retail pharmacy and investment in the Primary Care Clinic Villagemd.

But Walgreens made $ 1 billion in profits by hosting some of its Cencora actions, an organization of pharmaceutical solutions, and benefiting from its investment in Brightspring, a complete and community health service provider, very early. These are two of Walgreens’ best health investments.

The company’s operating cash flows in the second quarter were reached by $ 969 million in legal payments for the regulations related to opioids and a dispute with the virtual care company Everly Health Solutions, which alleged that Walgreens had broken the terms of a commercial contract during the Pandemic COVID-19.